Dazhi Fu

406 citations
11 papers · 290 indexed · 1 hit paper · h-index 7
Topics
Cancer-related molecular mechanisms research (3 papers)Circular RNAs in diseases (2 papers)Pancreatic function and diabetes (2 papers)
Partner nations
ChinaSaudi Arabia

In The Last Decade

Dazhi Fu

11 papers receiving 285 citations

Hit Papers

Induction of ferroptosis by ATF3 elevation alleviates cis...2021202620222024202150100150

Peers

Dazhi Fu
Comparison fields: 5 of 53
  • Molecular Biology 202
  • Cancer Research 152
  • Pulmonary and Respiratory Medicine 143
  • Oncology 47
  • Surgery 20
Replace Wei‐Jia Mo with:
Wei‐Jia Mo China
Gege Shu China
Abeba Zewdu United States
Wayne Glover United States
Anqi Dong China
Fan Chao China
Chengkai Jiang China
Yinli Zheng China
Silvia Cruz-Gil Spain
Xinhong Wang China
Dazhi Fu relative to Wei‐Jia Mo China Wei‐Jia Mo's profile →
Citations per field
00.5×4.1×
Wei‐Jia Mo · 1×
Citations per year

Countries citing papers authored by Dazhi Fu

Since Specialization
Citations

This map shows the geographic impact of Dazhi Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dazhi Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dazhi Fu more than expected).

Fields of papers citing papers by Dazhi Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dazhi Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dazhi Fu. The network helps show where Dazhi Fu may publish in the future.

Co-authorship network of co-authors of Dazhi Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Dazhi Fu. A scholar is included among the top collaborators of Dazhi Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dazhi Fu. Dazhi Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
#WorkIndexed citations
1 1
2 5
3 10
4
Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signalingbreakdown →
192
5 14
6 4
7 14
8 16
9 10
10 18
11 6

About Dazhi Fu

Dazhi Fu is a scholar working on Transplantation, Cancer Research and Hepatology, having authored 11 papers that have together received 290 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (3 papers), Circular RNAs in diseases (2 papers) and Pancreatic function and diabetes (2 papers). The work is most often cited by research in Cancer Research (152 citations), Pulmonary and Respiratory Medicine (143 citations) and Molecular Biology (202 citations). Dazhi Fu has collaborated with scholars based in China and Saudi Arabia. Frequent co-authors include Chunxiao Wang, Lei Yu, Rui Yu, Haiyang Liu, Ying Cheng, Hui He, Rui Yu, Yongfeng Liu, Hui He and Yongfeng Liu. Their work appears in journals such as BMC Genomics, Cell Cycle and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026